ModEMUS
Financiado
Modelling nanoparticle transport in the extracellular matrix improving drug del...
Modelling nanoparticle transport in the extracellular matrix improving drug delivery with ultrasounds
Cancer is the second most important cause of death in Europe, with an estimated 2.27 million new cases and 1.3 million deaths in 2020. The prerequisite for a successful medicinal therapy is that the drug reaches its target and tha...
Cancer is the second most important cause of death in Europe, with an estimated 2.27 million new cases and 1.3 million deaths in 2020. The prerequisite for a successful medicinal therapy is that the drug reaches its target and that toxicity towards healthy tissue is limited, however the systemic injection of drugs leads to less than 1 % of the drugs accumulating in solid tumours. Relying on the permeability of the blood vessel in cancer tumours, the encapsulation of drugs in nanoparticles (NPs) constitutes a promising approach for cancer treatment. However, the homogeneous distribution of NPs in the tumour tissue remains a challenge. To reach all cells in the tumour the NPs must cross the extracellular matrix (ECM), a major component of solid tumours consisting mainly of a network of collagen fibres embedded in a hydrophilic gel of proteoglycans. Together, they limit the diffusion of drugs across the tumour. Focused UltraSound (FUS) exposure has been reported to improve the delivery of NPs to tumour cells. FUS induces acoustic radiation force and cavitation that can lead to microstreaming or shock waves but the underlying mechanism(s) for the improved transport are not well understood. Successful delivery depends on many factors including the pathology, structure and composition of the diseased tissue, the characteristics of the NPs, and the exposure parameters of the FUS, making it a complex problem difficult to solve using an experimental approach. In this project, we will use molecular modelling to identify correlations between the molecular details of NPs and ECM, and FUS exposure parameters with NP transport across the ECM, creating a predictive model for FUS delivery of NPs and drugs to diseased tissue. The model, validated by experimental data, will contribute to the design of personalized medicine for improved NP-based drug delivery.
ver más
Duración del proyecto: 37 meses
Fecha Inicio: 2022-06-09
Fecha Fin: 2025-07-31
Fecha Fin: 2025-07-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-09
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2021-PF-01-01:
MSCA Postdoctoral Fellowships 2021
Cerrada
hace 3 años
Presupuesto
El presupuesto total del proyecto asciende a
211K€
Líder del proyecto
SINTEF AS
No se ha especificado una descripción o un objeto social para esta compañía.
N.D. |
Participante